Progressive supranuclear palsy (PSP) is a primary 4-repeat (4R) tauopathy characterized by prominent astrocytic pathology in addition to neuronal lesions. The hallmark astrocytic lesion in PSP is the tufted astrocyte—a tau-positive astrocyte with dense perisomatic and proximal process inclusions that form a distinctive "tufted" appearance on histology.[1][2] This page details the biology of tufted astrocytes, their role in PSP pathogenesis, and the consequences of astrocytic dysfunction for neuronal health and circuit integrity.
Astrocytes are essential for brain homeostasis—they buffer neurotransmitters, provide metabolic support to neurons, regulate blood flow, and maintain extracellular ion balance.[3] In PSP, the accumulation of hyperphosphorylated 4R tau in astrocytes disrupts these critical functions, contributing to network failure, excitotoxicity, and progressive clinical decline.
Tufted astrocytes exhibit several distinguishing morphological features that differentiate them from other glial tau inclusions:
Tufted astrocytes in PSP show a characteristic anatomical distribution that parallels the pattern of neuronal loss and clinical symptoms:
The distribution of tufted astrocytes correlates with the subcortical predilection of PSP and helps explain the early involvement of oculomotor function, postural control, and gait.[2:3][10]
The accumulation of tau in astrocytes involves multiple cellular pathways:
Extracellular tau uptake: Astrocytes can internalize extracellular tau species via endocytic pathways and receptor-mediated mechanisms, including heparan sulfate proteoglycans and LRP1.[11][12] This uptake allows astrocytes to clear pathological tau from the extracellular space but may also serve as a route for tau seeding within the astrocytic population.
Neuron-to-astrocyte transfer: Pathological tau may transfer from adjacent neurons through synaptic contacts or extracellular vesicles, exploiting the extensive astrocytic processes that ensheath synapses.[13]
Cellular vulnerability: Astrocytes in regions with high neuronal tau burden may be particularly susceptible to tau accumulation due to their intimate structural and functional relationships with neurons.[14]
Once tau accumulates in astrocytes, several proteostatic mechanisms become overwhelmed:
Autophagy-lysosomal dysfunction: Tau-laden astrocytes show reduced autophagic flux, leading to accumulation of tau within the cytosol.[15] This creates a self-perpetuating cycle where impaired degradation capacity allows toxic species to persist.
Ubiquitin-proteasome system impairment: Studies indicate that proteasomal function is compromised in astrocytes with tau inclusions, reducing their ability to clear misfolded tau species.[16]
Astrocytic stress response activation: The accumulation of tau triggers cellular stress responses, including activation of the unfolded protein response (UPR) and inflammatory signaling cascades.[17]
Astrocytes provide critical metabolic support to neurons through several mechanisms that are disrupted in PSP:
Under normal conditions, astrocytes take up glucose and convert it to lactate via glycolysis, then shuttle lactate to neurons as an energy substrate.[18] This astrocyte-neuron lactate shuttle (ANLS) is essential for maintaining neuronal energy demands, particularly during periods of high activity.
In PSP, tufted astrocytes show:
The metabolic coupling failure has several downstream consequences:
Astrocytes are the primary regulators of extracellular glutamate through the excitatory amino acid transporters EAAT1 (GLAST) and EAAT2 (GLT-1).[22] These transporters prevent excitotoxic accumulation of glutamate in the synaptic cleft and surrounding extracellular space.
In PSP, tufted astrocytes show:
The loss of glutamate transporter function contributes to PSP pathophysiology through:
Reactive astrocytes in PSP adopt a pro-inflammatory phenotype that amplifies neurodegeneration:
The relationship between astrocytes and microglia in PSP is bidirectional:
While initially described in Alzheimer's disease, the A1 (neurotoxic) and A2 (neuroprotective) astrocyte classification has relevance to PSP:
CBD is another 4R tauopathy but exhibits a distinct astrocytic lesion:
| Feature | PSP Tufted Astrocytes | CBD Astrocytic Plaques |
|---|---|---|
| Morphology | Dense perisomatic inclusions with radiating processes | Ring-like distal process tau positivity with relatively spared soma |
| Distribution | Subcortical nuclei, brainstem, motor cortex | Cortical gray matter, subcortical white matter |
| Clinical correlation | Vertical gaze palsy, postural instability, parkinsonism | Cortical sensory loss, apraxia, alien limb |
| Tau conformation | PSP-specific 4R tau fold | CBD-specific 4R tau fold |
This morphological distinction suggests that different 4R tau conformations (strains) may preferentially seed astrocytes in different brain regions, leading to the distinct clinical phenotypes of PSP and CBD.[35][36]
The basal ganglia motor circuit is particularly vulnerable to astrocytic pathology in PSP:
The brainstem circuits controlling eye movements are heavily affected:
Understanding astrocyte pathology in PSP suggests several therapeutic approaches:
This mechanism page connects with:
Komori T. Tau-positive glial inclusions in progressive supranuclear palsy and corticobasal degeneration. Neuropathology. 2008. ↩︎ ↩︎ ↩︎ ↩︎
Williams DR, Lees AJ. 'Progressive supranuclear palsy: clinicopathological concepts and diagnostic challenges'. The Lancet Neurology. 2009. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Kimelberg HK. 'Functions of mature astrocytes: a critical review'. Brain Research Reviews. 2009. ↩︎
Dickson DW, Rademakers R, Hutton ML. 'Progressive supranuclear palsy: neuropathology and genetics'. Acta Neuropathologica. 2007. ↩︎ ↩︎
Arima K, Murayama S, Mukoyama M, Inose T. Immunocytochemical and ultrastructural studies of neuronal and glial inclusions in the brainstem of patients with progressive supranuclear palsy. Acta Neuropathologica. 1992. ↩︎
Liu Y, Xie T, Wang Y, et al. Tau-positive astrocytes in the brains of patients with 4R-tauopathy. Acta Neuropathologica Communications. 2021. ↩︎
Whitwell JL, Avula R, Master A, et al. Disrupted thalamocortical connectivity in PSP and CBD. Neurology. 2011. ↩︎ ↩︎
Bhattacharya K, Kauffman MA, O'Neill E, et al. Oculomotor and brainstem nuclei in progressive supranuclear palsy. Brain. 2017. ↩︎ ↩︎ ↩︎ ↩︎
Cordato NJ, Halliday GM, McCann H, et al. 'Cortical involvement in Richardson''s syndrome and PSP-parkinsonism: a comparative study'. Acta Neuropathologica. 2002. ↩︎
Respondek G, Stamelou M, Kurz C, et al. The phenotypic spectrum of progressive supranuclear palsy. Movement Disorders. 2017. ↩︎ ↩︎
Perea JR, López E, Díez-Ballesteros JC, et al. Extracellular monomeric tau is internalized by astrocytes. Frontiers in Neuroscience. 2019. ↩︎
Rauch JN, Chen JJ, Sorum AW, et al. Tau internalization is a clathrin- and heparan sulfate proteoglycan-dependent process. PLoS One. 2018. ↩︎
Wang Y, Martinez-Vicente M, Krüger U, et al. 'Tau fragmentation, aggregation and transmission: implications for tauopathies'. Acta Neuropathologica. 2009. ↩︎
de Ceglia R, Ledri M, Caleo M, et al. Intercellular transfer of tau pathology in neurodegenerative diseases. Neural Regeneration Research. 2022. ↩︎
Martinez-Vicente M. Neuronal and glial autophagy in neurodegenerative diseases. FEBS Letters. 2015. ↩︎
Kahlson MA, Colodner KJ. 'Glial tau pathology in tauopathies: functional consequences'. Acta Neuropathologica Communications. 2021. ↩︎
Hoozemans JJM, van Haastert ES, Eikelenboom P, et al. Activation of the unfolded protein response is an early event in Alzheimer's disease and in progressive supranuclear palsy. Acta Neuropathologica. 2007. ↩︎
Pellerin L, Magistretti PJ. 'Glutamate uptake into astrocytes stimulates aerobic glycolysis: a mechanism coupling neuronal activity to glucose utilization'. Proceedings of the National Academy of Sciences USA. 1994. ↩︎ ↩︎
Brown AM, Ransom BR. Astrocyte glycogen and brain energy metabolism. Glia. 2007. ↩︎
Schilling T, Eder C. 'Astrocyte metabolism: implications for neurological disorders'. Trends in Pharmacological Sciences. 2015. ↩︎ ↩︎ ↩︎
Oberheim NA, Goldman SA, Nedergaard M. Heterogeneity of astrocytic form and function. Methods in Molecular Biology. 2012. ↩︎ ↩︎
Danbolt NC. Glutamate uptake. Progress in Neurobiology. 2001. ↩︎
Kinoshita Y, Oda Y, Yokoo H, et al. Glutamate transporter expression in astrocytes and formation of gliomas. Brain Tumor Pathology. 2001. ↩︎ ↩︎ ↩︎
Vercellino M, Merola A, Piacentini E, et al. Altered glutamate reuptake in progressive supranuclear palsy and corticobasal degeneration. Acta Neuropathologica. 2007. ↩︎ ↩︎ ↩︎
Nicholls DG. Mitochondrial dysfunction and glutamate excitotoxicity studied in primary neuronal cultures. Current Molecular Medicine. 2004. ↩︎ ↩︎
Coyle JT, Puttfarcken P. Oxidative stress, glutamate, and neurodegenerative disorders. Science. 1993. ↩︎
Mattson MP. Excitotoxicity and excitoprotection in vitro and in vivo. Advances in Experimental Medicine and Biology. 1999. ↩︎
Ishizawa K, Dickson DW. Microglial activation parallels system degeneration in progressive supranuclear palsy. Journal of Neuropathology and Experimental Neurology. 2001. ↩︎ ↩︎ ↩︎ ↩︎
Stevens B, Allen NJ, Vazquez LE, et al. The classical complement cascade mediates CNS synapse elimination. Cell. 2007. ↩︎ ↩︎
Liddelow SA, Guttenplan KA, Clarke LE, et al. Neurotoxic reactive astrocytes are induced by activated microglia. Nature. 2017. ↩︎ ↩︎
Glass CK, Saijo K, Winner B, et al. Mechanisms underlying inflammation in neurodegeneration. Cell. 2010. ↩︎
Clarke LE, Liddelow SA, Chakraborty C, et al. Normal aging induces A1-like astrocyte reactivity. Proceedings of the National Academy of Sciences USA. 2018. ↩︎
Zamanian JL, Xu L, Foo LC, et al. Genomic analysis of reactive astrogliosis. Journal of Neuroscience. 2012. ↩︎
Lee HG, Wheeler MA, Quintana FJ. Function and therapeutic value of astrocytes. Nature Reviews Neuroscience. 2022. ↩︎ ↩︎ ↩︎
Shi Y, Zhang W, Yang Y, et al. Structure-based classification of tauopathies. Nature. 2021. ↩︎ ↩︎
Vaquer-Alicea J, Diamond MI. Propagation of protein aggregation in neurodegenerative diseases. Annual Review of Biochemistry. 2019. ↩︎
Albin RL, Young AB, Penney JB. The functional anatomy of basal ganglia disorders. Trends in Neurosciences. 1989. ↩︎ ↩︎
Ropper AH. The progressive supranuclear palsy. Annals of Internal Medicine. 1983. ↩︎
Pedersen JT, Sigurdsson EM. Tau immunotherapy for Alzheimer's disease. Trends in Molecular Medicine. 2015. ↩︎
Wischik CM, Staff RT, Wischik DJ, et al. 'Tau aggregation inhibitor therapy: an exploratory phase 2 study in mild or moderate Alzheimer''s disease'. Journal of Alzheimer's Disease. 2015. ↩︎
DeVos SL, Miller RL, Schoch KM, et al. Tau reduction prevents neuronal loss and reverses pathological tau gene expression. Science Translational Medicine. 2017. ↩︎
Rothstein JD, Patel S, Regan MR, et al. Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature. 2005. ↩︎
Van Vliet EA, Ndode-Ekane XE, Lehto LJ, et al. Long-lasting alterations in hippocampal astrocyte metabolic support after status epilepticus. Neurobiology of Disease. 2020. ↩︎
Tikka TM, Koistinaho JE. Minocycline provides neuroprotection against N-methyl-D-aspartate toxicity in rat cortical cultures. Journal of Cerebral Blood Flow & Metabolism. 2001. ↩︎
Vlad SC, Miller DR, Kowall NW, Felson DT. Protective effects of NSAIDs on the development of Alzheimer disease. Neurology. 2008. ↩︎